Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch for persistent delirium in elderly subacute inpatients
ACTRN12609001020279Phase 3Terminated
- Sponsor
- Melbourne Health
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Rivastigmine patch with Placebo patch (2 arms). Primary endpoint: Peak delirium severity. Started Feb 2010; status: terminated.
02
Drugs
rivastigmine
03
Conditions
delirium
Beyond the preview
Go deeper on ACTRN12609001020279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001020279.